SCHEMBL2391059

SCHEMBL2391059

CCOC(=O)/C=C/c1cccc(-c2ccccc2)c1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 6/20 0.50
PTGER3 P43115 6/20 0.50
PTGER2 P43116 6/20 0.50
PTGER1 P34995 4/20 0.50
LMNA P02545 2/20 0.45
MAPT P10636 2/20 0.44
HSD17B1 P14061 1/20 0.44
HSD17B2 P37059 1/20 0.44
ALOX5 P09917 1/20 0.43
CA12 O43570 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
AKR1B10 O60218 1/20 0.42
AKR1B1 P15121 1/20 0.42
CA4 P22748 1/20 0.42
CA6 P23280 1/20 0.42
CA5A P35218 1/20 0.42
CA5B Q9Y2D0 1/20 0.42
CA1 P00915 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30671346 0.81 PDCD1 (0.47) LMNAMAPTHSD17B1HSD17B2CA12
SCHEMBL9857590 0.80 PTGER1 (0.67) PTGER4PTGER3PTGER2PTGER1LMNA
SCHEMBL16319072 0.80 PTGER4 (0.55) PTGER4PTGER3PTGER2PTGER1LMNA
SCHEMBL16319070 0.80 PTGER4 (0.55) PTGER4PTGER3PTGER2PTGER1LMNA
SCHEMBL39304 0.79 ALDH1A1 (0.48) LMNAMAPTHSD17B1HSD17B2ALOX5
SCHEMBL39303 0.79 ALDH1A1 (0.48) LMNAMAPTHSD17B1HSD17B2ALOX5
SCHEMBL1897191 0.77 MGAM (0.45) PTGER4PTGER3PTGER2PTGER1L3MBTL1
SCHEMBL15668890 0.77 HDAC8 (0.52) PTGER4PTGER3PTGER2PTGER1LMNA
SCHEMBL15668889 0.77 HDAC8 (0.52) PTGER4PTGER3PTGER2PTGER1LMNA
SCHEMBL7961856 0.77 PTGER3 (0.80) PTGER4PTGER3PTGER2PTGER1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE42700-E1 Induction of apoptosis in cancer cells SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-09-13 US disclosed
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 PTGER4 2670/4885PTGER3 2883/4885PTGER2 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.